anna

Childhood cancer: “New” immune system responds better to therapy

(Vienna, 9.8.2023) Scientists at St. Anna Children’s Cancer Research Institute and the Eberhard Karls University of Tübingen have shown that immunotherapy after stem cell transplantation effectively combats certain nerve tumors in children. Crucially, stem cells from a parent provide children with a new immune system that responds much better to immunotherapies. These results of an early clinical trial were published in the prestigious Journal of Clinical Oncology.

Childhood cancer: “New” immune system responds better to therapy Read More »

Automated testing of pediatric cancer therapies

With a novel High-Throughput-Screening method the efficacy of numerous drugs can be tested simultaneously. Researchers are now able to quickly and efficiently assess which substances are effective against certain tumors. A team led by Martin Distel, PhD, and Sabine Taschner-Mandl, PhD, of St. Anna Children’s Cancer Research Institute has now provided the first guide on how to use this method to test the sensitivity of childhood tumors to different drugs in zebrafish models. The study was published in the Journal npj Precision Oncology.

Automated testing of pediatric cancer therapies Read More »

Childhood cancer: Vulnerability in the immune response against metastases discovered

Scientists led by Sabine Taschner-Mandl, PhD, St. Anna Children’s Cancer Research Institute, and Nikolaus Fortelny, PhD, Paris Lodron University of Salzburg, are the first to analyze bone marrow metastases from childhood tumors of the nervous system using modern single-cell sequencing analysis. It turns out that cancer cells prevent cells in their environment from fighting the tumor – a process that could be reversed with medication. The findings were published in the renowned journal Nature Communications.

Childhood cancer: Vulnerability in the immune response against metastases discovered Read More »

Florian Grebien appointed as new Principal Investigator at St. Anna CCRI

Prof. Florian Grebien, PhD, is eager to understand why some childhood leukemias show poor treatment response and how this can be tackled. To this end, he is now establishing his own team at St. Anna Children’s Cancer Research Institute (St. Anna CCRI). “Prof. Grebien is an outstanding researcher. We have followed his scientific achievements for many years and are very pleased to have been able to recruit him as a Principal Investigator to St. Anna CCRI,” says Prof. Kaan Boztug, MD, Scientific Director of St. Anna CCRI.

Florian Grebien appointed as new Principal Investigator at St. Anna CCRI Read More »

International sarcoma meeting “EuSARC” hosted by St. Anna CCRI in Vienna

From May 18th to 20th, St. Anna Children’s Cancer Research Institute (St. Anna CCRI) welcomes scientists and physicians from Europe, the USA, and beyond, at the EuSARC 2023 meeting in Vienna. EuSARC is a Europe-wide group of scientists holding annual meetings to address the dire need for novel therapies in sarcomas, a group of poorly explored bone and soft tissue tumors.

International sarcoma meeting “EuSARC” hosted by St. Anna CCRI in Vienna Read More »

Drug combination shrinks childhood cancer in zebrafish

A combination therapy against childhood bone cancer is efficient in living organisms: if the tumor is transplanted into fish larvae and treated with certain drugs, it shrinks significantly or disappears completely. However, the journey will still take a while before these drugs can be applied in children, say Martin Distel, PhD, from St. Anna Children’s Cancer Research Institute and co-authors. The results were published in the journal Cancer Letters.

Drug combination shrinks childhood cancer in zebrafish Read More »

Ana Kutschat selected for training program by European Hematology Association (EHA) and EMBL-EBI

Ana Kutschat selected for training program by EHA and EMBL-EBI (Vienna, 21.12.2022) The European Hematology Association (EHA) and EMBL’s European Bioinformatics Institute (EMBL-EBI) selected Ana Kutschat, postdoc in Davide Seruggia´s research group at St. Anna Children´s Cancer Research Institute (St. Anna CCRI) as one of only 20 favored young scientists to participate in the 2023

Ana Kutschat selected for training program by European Hematology Association (EHA) and EMBL-EBI Read More »

Delighted to present at ASH: Three updates on the FORUM trial

Prof. Christina Peters, MD, from St. Anna Children’s Hospital and St. Anna CCRI presents new data showing a dire need for immunotherapy strategies tackling high-risk childhood leukemia at the Annual Meeting of the American Society of Hematology (ASH). Other updates from the same study (FORUM) confirm the superiority of total body irradiation prior to stem cell transplantation and the use of transplants from matched unrelated donors in children under the age of four with high-risk acute lymphoblastic leukemia (ALL).

Delighted to present at ASH: Three updates on the FORUM trial Read More »

How to make latest cancer therapies also available for children

How adult drugs from the group of MAP kinase inhibitors can also be used in children with cancer in a standardized manner worldwide has now been outlined in a statement in the renowned European Journal of Cancer. The authors of this review are stakeholders from all relevant fields, including Caroline Hutter, MD, PhD, scientist at St. Anna Children’s Cancer Research Institute, clinician at St. Anna Children’s Hospital and expert in the rare pediatric cancer Langerhans cell histiocytosis (LCH). Her goal is to test the most effective and tolerable MAP kinase inhibitor in a clinical trial, thus enabling rapid market approval and availability for children.

How to make latest cancer therapies also available for children Read More »

St. Anna CCRI attends “Better Medicines for Children Conference 2022”

St. Anna CCRI attends “Better Medicines for Children Conference 2022” (Vienna, 20.10.2022) We are happy to attend the “EFGCP Better Medicines for Children Conference 2022” with Ruth Ladenstein (Principal Investigator at St. Anna CCRI) presenting the EU funded “European Rare Disease Research Coordination and Support Action – ERICA” in the panel discussion “Rare diseases –

St. Anna CCRI attends “Better Medicines for Children Conference 2022” Read More »

Eva König wins Heribert-Konzett-Prize!

A great success! Dr. Eva König, principal investigator at St. Anna CCRI, is honored with the Heribert-Konzett-Prize of the Austrian Pharmacological Society (APHAR) for her scientific work on the interaction between immune and cancer cells. The prize is awarded to recognize the achievements of young scientists already conducting independent research in the field of experimental and clinical pharmacology and to encourage their further development.

Eva König wins Heribert-Konzett-Prize! Read More »